Impact of adherence on the cost-effectiveness of apixaban and rivaroxaban in stroke prevention among patients with atrial fibrillation in the United States
After incorporating adherence, apixaban 5 mg was a cost-effective alternative to rivaroxaban 20 mg for stroke prevention among elderly atrial fibrillation (AF) patients.
Authors
- Haluk Damgacioglu (ORCID: https://orcid.org/0000-0003-4361-4515)
- Ashish A. Deshmukh (ORCID: https://orcid.org/0000-0001-8936-8108)
- Ekere James Essien (ORCID: https://orcid.org/0000-0001-8157-8290)
- Rutugandha Paranjpe
- Hua Chen (ORCID: https://orcid.org/0000-0001-7889-8023)
- Bilqees Fatima (ORCID: https://orcid.org/0000-0002-7380-8049)
- Susan Abughosh (ORCID: https://orcid.org/0000-0002-8779-8523)
- Matthew A. Wanat (ORCID: https://orcid.org/0000-0003-4832-8200)
- Anjana Mohan (ORCID: https://orcid.org/0000-0002-1200-1153)
Institutions
- Medical University of South Carolina (US)
- University of Houston (US)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1080/14737167.2024.2398487
- Citations
- 1
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.40